Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

(NASDAQ:MOLN) Molecular Partners AG announced the presentation of new preclinical data for MP0632, a logic-gated Switch-DARPin T cell engager with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer (SITC) 2026 conference. The data support an attractive therapeutic window for MP0632, demonstrating potent and selective tumor cell killing with efficacy comparable to a clinical-stage benchmark T-cell engager but with a substantially improved safety profile. The preclinical results showed safe integration of CD2 co-stimulation, enabling sustained T-cell activity, and no detectable impact on primary human mesothelial or epithelial cells, as well as no evidence of mononuclear cell infiltration in the lung pleura of mice expressing human EpCAM and MSLN. These findings provide preclinical proof-of-concept that logic-gated Switch-DARPins can selectively target tumor-associated antigens (TAAs) considered undruggable for TCEs to date, specifically turning MSLN and EpCAM into a 'clean' target pair. The results build on previously presented data demonstrating regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tissue expressing only one antigen. The Switch-DARPin design allowed for safe use of potent co-stimulation for efficient tumor cell killing with a low cytokine release profile. The preclinical data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, such as ovarian, endometrial, lung, and pancreatic cancers. The SITC poster, titled 'MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM,' was presented as Poster #1072, a Top 150 SITC 2026 Abstract, on 07 Nov 2026 at the Phoenix Convention Center. MP0632 is designed to activate T cells only when both MSLN and EpCAM are present, enabling reversible, dual-target-dependent un-masking of the CD3 binder for tumor-localized efficacy while avoiding systemic T cell activity and limiting impact on healthy tissues. The built-in CD2 co-stimulation maintains potent and sustained tumor-localized T cell function. Molecular Partners' lead medicine, MP0712, targets DLL3 and is armed with 212 Pb, advancing in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers. The company has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners was founded in 2004 and has offices in Zurich, Switzerland and Concord, MA, USA.

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70

(NASDAQ:MOLN) Molecular Partners AG announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the tumor-associated antigen CD70. MP0730 is the third program in the company's pipeline of targeted alpha radiotherapeutics. A first-in-human program for MP0730 is expected to start in mid-2027. Preclinical data on MP0730 were presented at the Discovery on Target – Radioligand Therapies conference on October 1, 2026, in Boston, MA. The preclinical data demonstrated an attractive biodistribution profile of the CD70-targeting Radio-DARPin lead candidate in tumor-bearing mice, with strong and sustained tumor uptake relative to healthy tissues, including kidney, liver, and blood. Daniel Steiner, Ph.D., SVP Targeted Radiotherapeutics of Molecular Partners, stated that the selection of MP0730 marks an important milestone and that CD70’s expression profile and MP0730’s properties provide a foundation for achieving a favorable therapeutic index. CD70 is a clinically validated target, demonstrated through CAR-T cell therapies, and is overexpressed in clear cell renal cell carcinoma (ccRCC) and other cancer indications. CD70 expression is maintained in metastases and limited in healthy tissues. ccRCC is inherently resistant to conventional cytotoxic therapies due to a robust DNA repair mechanism. Targeted alpha therapy induces difficult-to-repair double-strand breaks in tumor cells, offering a new avenue for patients with hard-to-treat cancers such as ccRCC. Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors to unlock a broad range of cancer targets and indications. The company tailors its radiotherapeutic candidates by matching vector and isotope properties with disease and target biology. Radio-DARPins are designed for precise delivery of potent radioactive payloads to tumor lesions and address limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering. The Radio-DARPins support swapping of chelator and isotope while maintaining comparable biodistribution. DARPin therapeutics have been clinically validated across several disease areas, tested in more than 2,500 patients globally, and developed through to the registrational stage. The company’s lead medicine MP0712, targeting DLL3 and armed with 212 Pb, is advancing in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers. Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. The company was founded in 2004 and has offices in Zurich, Switzerland and Concord, MA, USA.

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

(NASDAQ: MOLN) Molecular Partners AG announced the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept (POC) study of MP0317 in combination with chemoimmunotherapy for advanced biliary tract carcinoma (TACTIC), also known as cholangiocarcinoma. The randomized, multicenter TACTIC study in France aims to recruit 75 patients, with a 2-to-1 design, allocating 50 patients to the experimental arm and 25 to the control arm. Nine expert trial sites are now activated and patient treatment is ongoing. A data update from the trial is expected in 2027, with trial completion in 2028. A trial-in-progress poster on the MP0317 Phase 2 study has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Molecular Partners completed a Phase 1 dose-escalation study of MP0317 in patients with advanced solid tumors, with 46 patients treated across 9 dose levels. The company projects that MP0317 could improve 12-month progression-free survival rate of patients with advanced cholangiocarcinoma compared to standard-of-care alone.

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

(NASDAQ: MOLN) Molecular Partners AG announced its development of bispecific Radio-DARPins to engage multiple tumor targets simultaneously, aiming to improve precision and therapeutic efficacy. The company presented these approaches at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US, on July 15, 2026. Molecular Partners’ lead Radio-DARPin candidate MP0712, co-developed with Orano Med and targeting delta-like ligand 3 (DLL3), is in a multicenter US Phase 1/2a trial, following successful generation of first imaging and dosimetry data from a compassionate care program. The second candidate, MP0726, targets mesothelin MSLN and is differentiated by its ability to selectively bind membrane-bound MSLN, with work towards first human imaging expected this year. The company expects to announce a third Radio-DARPin program targeting a different tumor target in 2026. Molecular Partners has established partnerships with Orano Med, Eckert & Ziegler, and PanTera for the development and supply of radiopharmaceuticals. The company’s proprietary Radio-DARPin platform is designed to address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake.

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

(NASDAQ: MOLN) Molecular Partners AG announced ongoing dosing in the first cohort of its US multicenter Phase 1/2a trial of MP0712, a 212 Pb-based DLL3-targeted Radio-DARPin, co-developed with Orano Med. Five centers are open and recruiting, with each patient receiving up to 4 doses of MP0712 within their assigned dose level, and the Phase 1 study containing up to 4 dose levels (cohorts). Initial data from the MP0712 Phase 1/2a study are expected within the next months, with comprehensive efficacy data expected in 2027. Additional compassionate care work has been initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225 Ac-loaded DLL3 Radio-DARPin (MP0714), with PanTera supplying 225 Ac. MP0726, targeting MSLN, is planned to start first-in-human imaging in H2 2026, and two INDs are planned in 2027, with a new target nomination in H2 2026. Preclinical data presented at the 3rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China, showed highly comparable biodistribution profiles of two Radio-DARPin candidates labeled with 177 Lu or 203 Pb. Molecular Partners has established partnerships with Orano Med, Eckert & Ziegler, and PanTera for the development and supply of radioisotopes.

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

(NASDAQ: MOLN) Molecular Partners AG and Orano Med announced that the first patients were dosed in the ongoing US multicenter Phase 1/2a study of drug candidate MP0712. Five centers are open and actively recruiting in the US, with additional sites planned to open this year. MP0712 targets the tumor-associated protein delta-like ligand 3 (DLL3), which is present in over 85% of SCLC tumors, and carries the therapeutic payload 212 Pb. Patients in the Phase 1/2a study receive up to four doses of 212 Pb-labeled MP0712 within their assigned dose level cohort, and the study contains up to four dose levels. Dosing of patients is ongoing in cohort 1, with patients moving to repeat dosing. Initial data from the MP0712 Phase 1/2a study are expected in the upcoming months, with a more comprehensive dataset on safety and efficacy in 2027. The company projects that initial study data will be reported in 2026 and comprehensive efficacy data in 2027.

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

(NASDAQ: MOLN) Molecular Partners AG announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479) is actively recruiting patients with dosing ongoing in the first cohort. MP0712 is a 212 Pb-based Radio-DARPin Therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. DLL3 is present in >85% of tumors of patients with SCLC and other aggressive neuroendocrine tumors, while expression in healthy tissues is low. Molecular Partners and the team of Dr. Mike Sathekge at the Nuclear Medicine Research Institute (NuMeRI) in South Africa presented first patient imaging and dosimetry data on MP0712 at the 8th Theranostics World Congress (TWC) in January 2026. The data, generated with MP0712 carrying the diagnostic isotope 203 Pb, showed specific uptake in tumor lesions. Molecular Partners expects to share initial clinical data from this study in 2026.

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

Molecular Partners AG (NASDAQ:MOLN) announced corporate highlights and unaudited financial results for Q1 2026. The company reported a strong financial position with cash and short-term time deposits of CHF 79 million (approximately USD 100 million) as of March 31, 2026, providing runway until late 2027. The lead Radio-DARPin program, MP0712, is advancing in a Phase 1/2a trial with four clinical sites open and initial clinical data expected in 2026. New data support an isotope-agnostic strategy for expanding the pipeline, and multiple clinical and pre-clinical programs are progressing. All motions at the Annual General Meeting were approved, including the election of Clare Fisher to the Board of Directors.

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

Molecular Partners AG (NASDAQ:MOLN), a clinical-stage biotech company based in Switzerland and the USA, announced its participation and presentations at several upcoming scientific conferences in May 2026. The company will present data on its lead Radio-DARPin candidate MP0712 for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC) at events in the USA and Switzerland. Molecular Partners is pioneering a novel class of protein drugs known as DARPin therapeutics, with proprietary programs in various stages of pre-clinical and clinical development. The company also collaborates with leading pharmaceutical companies and academic centers. This announcement highlights the company's ongoing clinical development and engagement with the scientific community.

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners AG announced positive Phase 1 clinical data for MP0317, a tumor-localized CD40 agonist, published in Nature Cancer. The Phase 1 study demonstrated a favorable safety profile and proof-of-mechanism, with one unconfirmed partial response and 14 patients achieving stable disease among 46 patients with advanced solid tumors. A randomized Phase 2 investigator-initiated trial in front-line cholangiocarcinoma is now open with patient dosing ongoing, aiming to recruit 75 patients in France. The study will assess MP0317 in combination with standard-of-care chemotherapy and anti-PDL1 therapy. These results support further clinical evaluation of MP0317 in combination treatment settings.